FY2025 · ended Dec 31, 2025 · Revenue $8,000, +0.0% YoY · Filed Mar 19, 2026
Genelux Corporation (GNLX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $8,000 and a net loss of $32.1 million. Free cash flow was -$26.4 million. As of Jun 30, 2026 it held $18.7 million in cash and investments and $2.4 million in total debt.
Revenue
$8,000
+0.0% vs prior year
Net income
$-32.15M
-7.6% vs prior year
Operating cash flow (TTM)
$-25.28M
-12.1% vs year-ago TTM
Free cash flow (TTM)
$-28.68M
-25.7% vs year-ago TTM
EPS
$-0.86
+9.5% vs prior year
Dividend per share
None
Shares outstanding
44.81M
+18.7% vs prior year
Net cash
$16.26M
as of Jun 30, 2026
Operating margin
-415175.0%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GNLX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Westlake Village, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1231457
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
|---|---|---|---|
| Revenue | $8,000 | $8,000 | $170,000 |
| Operating income | -$33.2M | -$31.7M | -$24.2M |
| Net income | -$32.1M | -$29.9M | -$28.3M |
| Diluted EPS | -$0.86 | -$0.95 | -$1.16 |
| Operating cash flow | -$25.3M | -$21.2M | -$20.3M |
| Free cash flow | -$26.4M | -$21.6M | -$21.3M |
| Total assets | $19.0M | $34.7M | $27.9M |
| Total liabilities | $7.5M | $8.4M | $8.4M |
| Stockholders' equity | $11.5M | $26.3M | $19.5M |
| Cash and investments | $14.6M | $30.9M | $23.2M |
| Total debt | $1.7M | $1.9M | $3.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 22, 2026 | Jun 16, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| ARS | Annual report to shareholders | Apr 29, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Material agreement
|
Mar 19, 2026 | Mar 19, 2026 |
| 10-K | Annual report | Mar 19, 2026 | Dec 31, 2025 |
All 359 Genelux Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.